Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.3 USD | +1.34% | +6.29% | -20.42% |
May. 02 | Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed | MT |
May. 02 | Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.42% | 19.27B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B | |
+19.33% | 11.64B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- BMO Capital Cuts Price Target on Alnylam Pharmaceuticals to $234 From $250, Maintains Outperform Rating